Observational studyThe lancet. HIV2015
Comparative effectiveness of immediate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: observational cohort study.
Observational study in The lancet. HIV, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 1 synthesis or guideline pooled it, 68 citations in OpenAlex.
- From CD4-Based Initiation to Treating All HIV-Infected Adults Immediately: An Evidence-Based Meta-analysis.Frontiers in immunology · 2018Pooled it
- Immediate Antiretroviral Therapy Reduces Risk of Infection-Related Cancer During Early HIV Infection.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2016Trial
- Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection.The New England journal of medicine · 2015Trial
- Timing of urate-lowering therapy and risk of kidney failure and mortality in CKD: an application of the parametric G-formula.Clinical kidney journal · 2026Article
- Applications and reporting of causal inference modelling in infectious disease studies: A systematic review.Infectious Disease Modelling · 2026Article
- Estimating average causal effects with incomplete exposure and confounders.Journal of causal inference · 2026Article
- Enhanced Cohort Methods for HIV Research and Epidemiology (ENCORE): Protocol for a Nationwide Hybrid Cohort for Transgender Women in the United States.JMIR research protocols · 2024Article
- Target trial emulation for comparative effectiveness research with observational data: Promise and challenges for studying medications for opioid use disorder.Addiction (Abingdon, England) · 2024Article
- Demographic and clinical factors correlated with clinical outcomes among people with HIV treated by antiretroviral therapy: a retrospective cohort study.BMC infectious diseases · 2024Article
- Rapid antiretroviral therapy and treatment outcomes among people living with HIV: exploring the mediating roles of medication adherence.Frontiers in public health · 2024Article
- Evaluating Model Specification When Using the Parametric G-Formula in the Presence of Censoring.American journal of epidemiology · 2023Article
- Survival times of HIV/AIDS in different AIDS Diagnostic and Treatment Guidelines from 2006 to 2020 in Liuzhou, China.BMC public health · 2023Article
- Long-Term Benefits from Early Antiretroviral Therapy Initiation in HIV Infection.NEJM evidence · 2023Article
- Sustained virological response after treatment with direct antiviral agents in individuals with HIV and hepatitis C co-infection.Journal of the International AIDS Society · 2022Article
- Motivations and Barriers to Routine HIV Testing Among Men Who Have Sex with Men in New York City.AIDS and behavior · 2022Article
- MULTIPLY ROBUST ESTIMATORS OF CAUSAL EFFECTS FOR SURVIVAL OUTCOMES.Scandinavian journal of statistics, theory and applications · 2022Article
- Benchmarking Observational Analyses Before Using Them to Address Questions Trials Do Not Answer: An Application to Coronary Thrombus Aspiration.American journal of epidemiology · 2022Article
- Article
- Effect of Late Testing and Antiretroviral Treatment on Mortality Among People Living With HIV in the Era of Treat-All in Guangdong Province, China, 1992-2018: A Cohort Study.Frontiers in public health · 2022Article
- Parametric g-formula implementations for causal survival analyses.Biometrics · 2021Article
Corrections and comments
- Commented on by
Authors and funding
30 authors at 19 institutions in 7 countries.
Funding
Abstract
backgroundRecommendations have differed nationally and internationally with respect to the best time to start antiretroviral therapy (ART). We compared effectiveness of three strategies for initiation of ART in high-income countries for HIV-positive individuals who do not have AIDS: immediate initiation, initiation at a CD4 count less than 500 cells per μL, and initiation at a CD4 count less than 350 cells per μL.
methodsWe used data from the HIV-CAUSAL Collaboration of cohort studies in Europe and the USA. We included 55,826 individuals aged 18 years or older who were diagnosed with HIV-1 infection between January, 2000, and September, 2013, had not started ART, did not have AIDS, and had CD4 count and HIV-RNA viral load measurements within 6 months of HIV diagnosis. We estimated relative risks of death and of death or AIDS-defining illness, mean survival time, the proportion of individuals in need of ART, and the proportion of individuals with HIV-RNA viral load less than 50 copies per mL, as would have been recorded under each ART initiation strategy after 7 years of HIV diagnosis. We used the parametric g-formula to adjust for baseline and time-varying confounders.
findingsMedian CD4 count at diagnosis of HIV infection was 376 cells per μL (IQR 222-551). Compared with immediate initiation, the estimated relative risk of death was 1·02 (95% CI 1·01-1·02) when ART was started at a CD4 count less than 500 cells per μL, and 1·06 (1·04-1·08) with initiation at a CD4 count less than 350 cells per μL. Corresponding estimates for death or AIDS-defining illness were 1·06 (1·06-1·07) and 1·20 (1·17-1·23), respectively. Compared with immediate initiation, the mean survival time at 7 years with a strategy of initiation at a CD4 count less than 500 cells per μL was 2 days shorter (95% CI 1-2) and at a CD4 count less than 350 cells per μL was 5 days shorter (4-6). 7 years after diagnosis of HIV, 100%, 98·7% (95% CI 98·6-98·7), and 92·6% (92·2-92·9) of individuals would have been in need of ART with immediate initiation, initiation at a CD4 count less than 500 cells per μL, and initiation at a CD4 count less than 350 cells per μL, respectively. Corresponding proportions of individuals with HIV-RNA viral load less than 50 copies per mL at 7 years were 87·3% (87·3-88·6), 87·4% (87·4-88·6), and 83·8% (83·6-84·9).
interpretationThe benefits of immediate initiation of ART, such as prolonged survival and AIDS-free survival and increased virological suppression, were small in this high-income setting with relatively low CD4 count at HIV diagnosis. The estimated beneficial effect on AIDS is less than in recently reported randomised trials. Increasing rates of HIV testing might be as important as a policy of early initiation of ART.
fundingNational Institutes of Health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.